Helping you and your staff get back to workplace productivity

The Quest Diagnostics Back to Work program helps your employees manage their risk of SARS-CoV-2 (COVID-19) exposure in order to support a return to work. This implementation guide leads you through the step-by-step process for establishing the program, and outlines the roles and expectations for you, your employees, and Quest Diagnostics.

For more information on COVID-19, please visit QuestDiagnostics.com/COVID-19

Our Back to Work solution can help you:

- Follow federal and state health and safety guidelines
- Keep doors open during the pandemic
- Help speed up time to return productivity back to pre-pandemic levels
- Instill confidence in employees that they work for an employer dedicated to employee health and safety
- Strengthen your reputation in the community as an employer of choice that is committed to employee well-being even during times of crisis
How the Back to Work program works

We’ve developed a standard approach that can serve as an example for helping employees get back to the workplace. Every organization has different challenges and needs—and we work with every organization to develop the approach that’s right for them.

Quest will set up an account for the organization and the participants to optimize operations. The Back to Work program supports either employer or third-party billing.

Quest and organization sign contract

Each relationship is unique and each organization has different needs. By working together, we can clearly define the program up front, and articulate each of our obligations throughout the life of the program.

This will also allow Quest to commit the necessary resources and testing capacity to help ensure performance.

Account setup

Organization provides roster of employees

An email or text message is sent to eligible employees and includes a custom link associated with the employer’s account.

Emails to participants initiating the program and directing them to testing website

Prior to any access to the system, the participant will be required to verify their identity with their unique identifier, matched against the provided roster.

Participants complete screening questionnaire, verify identity, and provide consent

As part of our commitment to patient privacy, we require tacit approval and consent from the participants for the sharing of any health information, including reporting back to the Centers for Disease Control and Prevention and the organization on the results of any SARS-CoV-2 (COVID-19) testing.

Employers upload a roster of employees eligible for SARS-CoV-2 (COVID-19) testing in Excel to Quest.
Participant will provide sample for SARS-CoV-2 (COVID-19) molecular testing either at a retail partner convenient to the employee's home or via an authorized retail location.

- If result is positive, do not allow employee to return to work and connect to next steps of care
- Decisions to allow workers with COVID-19 to return to work may follow either a symptom-based, time-based, or test-based strategy

Employees are alerted via email when test results are ready

- MyQuest uses patient-friendly terms to help interpret the results
- Results can be printed or shared via email

Each participant will be encouraged to sign up for a MyQuest account.

This free and secure portal allows participants to easily view their test results online and schedule appointments at Patient Service Centers (PSCs).

Depending on the program selected by the organization, the employee could schedule an appointment at a PSC for a SARS-CoV-2 (COVID-19) Antibody Immunoglobulin G (IgG) test

Employer administrators can review and verify employee participation status and results through MyQuest.

- Daily email reports display program engagement and results
The antibody tests (sometimes known as the serology tests or IgG tests) are intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. Results are for the detection of SARS-CoV-2 antibodies. IgG antibodies to SARS-CoV-2 are generally detectable in blood several days after initial infection, although the duration of time antibodies are present post-infection is not well characterized. At this time, it is unknown for how long antibodies persist following infection and if the presence of antibodies confers protective immunity. Individuals may have detectable virus present for several weeks following seroconversion. Negative results do not preclude acute SARS-CoV-2 infection. If acute infection is suspected, molecular testing for SARS-CoV-2 is necessary. The antibody test should not be used to diagnose acute SARS-CoV-2 infection. False positive results for the antibody test may occur due to cross-reactivity from pre-existing antibodies or other possible causes.

- The antibody tests and the molecular tests (together “All tests”) have not been FDA cleared or approved;
- All tests have been authorized by FDA under EUAs for use by authorized laboratories;
- The antibody tests have been authorized only for the detection of IgG antibodies against SARS-CoV-2, not for any other viruses or pathogens;
- The molecular tests have been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens; and,
- All tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.